8-K: Contineum Launches Global Phase 2 IPF Trial for PIPE-791

Contineum Therapeutics has initiated a global Phase 2 clinical trial for PIPE-791 to treat idiopathic pulmonary fibrosis, with results expected by June 2028.

Summary

• Contineum Therapeutics, Inc. submitted details for its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis (IPF) to the ClinicalTrials.gov Protocol Registration and Results System (PRS) on December 8, 2025.
• The trial is a 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled study evaluating once-daily dosing of PIPE-791 in IPF patients.
• Approximately 324 subjects are expected to be enrolled globally.
• The primary objectives are to assess safety and tolerability, and efficacy will be measured by the change from baseline in absolute forced vital capacity (FVC) at week 26.
• The trial is expected to be completed in June 2028.
• The trial design and launch strategy were informed by prior regulatory engagement and completed Phase 1 clinical trials.
• The company plans to commence the trial internationally and add countries as regulatory approvals become available.

Sentiment

Score: 7

Explanation: The initiation of a global Phase 2 trial for a significant indication like IPF is a positive development for a biotechnology company. The trial design is robust, and it follows regulatory engagement and successful Phase 1 trials. However, the inherent risks of clinical development, as explicitly stated, temper the overall sentiment.

Positives

• Initiation of a global Phase 2 clinical trial for PIPE-791 in idiopathic pulmonary fibrosis (IPF), addressing a significant unmet medical need.
• Trial design was informed by prior regulatory engagement and successful Phase 1 clinical trials, suggesting a well-considered development path.
• The trial is designed to enroll a substantial number of subjects (approximately 324 globally), providing robust data for safety, tolerability, and efficacy.

Risks

• Uncertainty inherent in clinical drug development.
• Unpredictability and lengthy process for obtaining regulatory approvals for clinical trial protocols and ultimate regulatory approval for PIPE-791.
• The company's ability to successfully develop PIPE-791.
• The company's ability to achieve projected development goals within expected timeframes.
• Risk that results from earlier trials (Phase 1) may not be predictive of future trial results (Phase 2).
• Risks related to adverse side effects of PIPE-791.
• Risks related to reliance on third-party partners to conduct certain activities on the company's behalf.
• Smaller than anticipated market opportunities for the company's products and product candidates.
• Manufacturing risks.
• Competition from other therapies or products.
• Matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations.
• Risks affecting the company's future operating results and financial performance.
• Risks affecting the timing of clinical trial activities and reporting results.
• Risks affecting the availability or commercial potential of the company's products and drug candidates.

Future Outlook

The company expects the global Phase 2 clinical trial for PIPE-791 in IPF to be completed in June 2028. It plans to commence the trial internationally and progressively add more countries as regulatory approvals are secured.

Management Comments

• We expect to enroll approximately 324 subjects globally in a trial designed to assess safety and tolerability, as well as efficacy measured by the change from baseline in absolute forced vital capacity (FVC) at week 26.
• We expect the trial to be completed in June 2028.
• Our trial design and launch strategy was informed by regulatory engagement on an earlier draft protocol and by our completed Phase 1 clinical trials.
• We expect to commence the trial internationally, and to add countries as regulatory approvals become available.

Industry Context

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease with a significant unmet medical need. The initiation of a Phase 2 clinical trial for a novel therapeutic like PIPE-791 represents a crucial step in addressing this challenging condition, potentially offering a new treatment option in an area where current therapies have limitations.

Stakeholder Impact

• Shareholders: Potential for increased valuation if PIPE-791 demonstrates positive results in Phase 2, but also exposure to clinical trial risks.
• Patients with IPF: Potential for a new, effective treatment option for a severe disease.
• Employees: Continued employment and potential for growth within the company as the pipeline advances.
• Regulatory Authorities: Will monitor the trial's progress and data for future approval considerations.

Next Steps

• Posting of trial details on ClinicalTrials.gov upon approval by PRS.
• Commencement of the global Phase 2 clinical trial internationally.
• Adding more countries to the trial as regulatory approvals become available.
• Completion of the Phase 2 clinical trial by June 2028.

Key Dates

Keywords

Contineum Therapeutics, PIPE-791, Idiopathic Pulmonary Fibrosis, IPF, Phase 2 clinical trial, biotechnology, drug development, clinical trials, pulmonary disease, pharmaceuticals